Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Carbonic anhydrase I as a new plasma biomarker for prostate cancer.

Takakura M, Yokomizo A, Tanaka Y, Kobayashi M, Jung G, Banno M, Sakuma T, Imada K, Oda Y, Kamita M, Honda K, Yamada T, Naito S, Ono M.

ISRN Oncol. 2012;2012:768190. doi: 10.5402/2012/768190. Epub 2012 Nov 19.

2.

Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney.

Yokomizo A, Takakura M, Kanai Y, Sakuma T, Matsubara J, Honda K, Naito S, Yamada T, Ono M.

Cancer Biomark. 2011-2012;10(3-4):175-83. doi: 10.3233/CBM-2012-0243.

PMID:
22674303
3.

Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.

Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al.

Urology. 1995 Aug;46(2):187-94.

PMID:
7542820
4.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd.

J Urol. 2004 Oct;172(4 Pt 1):1302-5.

PMID:
15371828
5.

Multigene methylation analysis for detection and staging of prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

6.

Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.

Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, Salciccia S.

BJU Int. 2012 Dec;110(11):1661-5. doi: 10.1111/j.1464-410X.2012.11146.x. Epub 2012 May 4.

7.

Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray.

Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, Matsubara J, Sakuma T, Kuwabara H, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Shimahara M, Yasunami Y, Ino Y, Tsuchida A, Aoki T, Tsugane S, Yamada T.

Cancer Sci. 2011 Mar;102(3):630-8. doi: 10.1111/j.1349-7006.2010.01818.x. Epub 2010 Dec 28.

8.

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.

Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H, Lilja H.

J Urol. 2002 Nov;168(5):1917-22. Erratum in: J Urol 2003 Jan;169(1):295.

PMID:
12394676
10.

Prostate cancer screening in the Tyrol, Austria: experience and results.

Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.

Eur J Cancer. 2000 Jun;36(10):1322-35. Retraction in: Eur J Cancer. 2012 Jan;48(2):286.

PMID:
10882875
11.

Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.

Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW.

Clin Prostate Cancer. 2004 Jun;3(1):49-53.

PMID:
15279691
12.

Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.

Törnblom M, Norming U, Adolfsson J, Becker C, Abrahamsson PA, Lilja H, Gustafsson O.

Urology. 1999 May;53(5):945-50.

PMID:
10223488
13.

Prostate cancer screening in Tyrol, Austria: experience and results.

Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G.

Eur Urol. 1999;35(5-6):523-38.

PMID:
10325519
14.

Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.

Sardana G, Jung K, Stephan C, Diamandis EP.

J Proteome Res. 2008 Aug;7(8):3329-38. doi: 10.1021/pr8003216. Epub 2008 Jun 26.

PMID:
18578523
16.

Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray.

Matsubara J, Honda K, Ono M, Sekine S, Tanaka Y, Kobayashi M, Jung G, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Yamada T.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2195-203. doi: 10.1158/1055-9965.EPI-11-0400. Epub 2011 Aug 9.

18.
19.

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H.

Prostate. 2001 Oct 1;49(2):101-9.

PMID:
11582588
20.

Supplemental Content

Support Center